Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 9/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 6/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13222651 | 0.84 | GSK3B (0.38) | GRIA2GSK3BDYRK1A | |
| SCHEMBL10114955 | 0.83 | NPY5R (0.45) | GRIA2NPY5RABL1AAK1GSK3B | |
| SCHEMBL10133536 | 0.81 | CCR8 (0.37) | GRIA2NPY5RJAK1 | |
| SCHEMBL10114953 | 0.77 | NPY5R (0.53) | GRIA2NPY5RABL1AAK1 | |
| SCHEMBL14424386 | 0.77 | NPY5R (0.53) | GRIA2NPY5RABL1AAK1 | |
| SCHEMBL14627691 | 0.73 | GRIA2 (0.42) | GRIA2NPY5RABL1AAK1 | |
| SCHEMBL10114818 | 0.73 | GRIA2 (0.42) | GRIA2NPY5RABL1AAK1 | |
| SCHEMBL10114823 | 0.72 | GRIA2 (0.40) | GRIA2NPY5RABL1AAK1 | |
| SCHEMBL14424639 | 0.72 | GRIA2 (0.40) | GRIA2NPY5RABL1AAK1 | |
| SCHEMBL10134454 | 0.71 | POLB (0.47) | GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | GRIA2 334/4885NPY5R 1/4885ABL1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.